Alnylam Pharmaceuticals, Inc. $ALNY Stock Holdings Lifted by WINTON GROUP Ltd

WINTON GROUP Ltd grew its position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 92.5% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 6,800 shares of the biopharmaceutical company’s stock after purchasing an additional 3,267 shares during the period. WINTON GROUP Ltd’s holdings in Alnylam Pharmaceuticals were worth $3,101,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently made changes to their positions in ALNY. OFI Invest Asset Management grew its stake in shares of Alnylam Pharmaceuticals by 5.8% in the 3rd quarter. OFI Invest Asset Management now owns 403 shares of the biopharmaceutical company’s stock valued at $184,000 after buying an additional 22 shares in the last quarter. Howard Capital Management Inc. raised its position in Alnylam Pharmaceuticals by 2.9% during the third quarter. Howard Capital Management Inc. now owns 854 shares of the biopharmaceutical company’s stock valued at $389,000 after acquiring an additional 24 shares in the last quarter. Frank Rimerman Advisors LLC lifted its stake in Alnylam Pharmaceuticals by 2.0% in the third quarter. Frank Rimerman Advisors LLC now owns 1,251 shares of the biopharmaceutical company’s stock valued at $570,000 after acquiring an additional 24 shares during the last quarter. Coastal Bridge Advisors LLC lifted its stake in Alnylam Pharmaceuticals by 2.3% in the third quarter. Coastal Bridge Advisors LLC now owns 1,097 shares of the biopharmaceutical company’s stock valued at $500,000 after acquiring an additional 25 shares during the last quarter. Finally, Meridian Financial Advisors LLC grew its position in Alnylam Pharmaceuticals by 3.5% in the third quarter. Meridian Financial Advisors LLC now owns 828 shares of the biopharmaceutical company’s stock worth $378,000 after acquiring an additional 28 shares in the last quarter. 92.97% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several brokerages have recently commented on ALNY. Morgan Stanley dropped their price target on shares of Alnylam Pharmaceuticals from $495.00 to $408.00 and set an “equal weight” rating on the stock in a research note on Friday, January 30th. Chardan Capital decreased their price objective on shares of Alnylam Pharmaceuticals from $475.00 to $425.00 and set a “buy” rating for the company in a report on Friday, February 13th. Needham & Company LLC lowered their target price on shares of Alnylam Pharmaceuticals from $529.00 to $510.00 and set a “buy” rating on the stock in a research report on Thursday, February 12th. Stifel Nicolaus raised their target price on Alnylam Pharmaceuticals from $495.00 to $508.00 and gave the company a “buy” rating in a report on Thursday, December 11th. Finally, Wall Street Zen cut Alnylam Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Saturday, February 14th. One research analyst has rated the stock with a Strong Buy rating, twenty-two have given a Buy rating and five have given a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $477.96.

Insider Transactions at Alnylam Pharmaceuticals

In other Alnylam Pharmaceuticals news, EVP Tolga Tanguler sold 1,598 shares of Alnylam Pharmaceuticals stock in a transaction that occurred on Monday, March 2nd. The stock was sold at an average price of $327.65, for a total value of $523,584.70. Following the transaction, the executive vice president directly owned 36,606 shares of the company’s stock, valued at $11,993,955.90. The trade was a 4.18% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, EVP Jeffrey V. Poulton sold 2,206 shares of the company’s stock in a transaction that occurred on Monday, March 2nd. The stock was sold at an average price of $327.65, for a total value of $722,795.90. Following the transaction, the executive vice president owned 64,273 shares of the company’s stock, valued at approximately $21,059,048.45. This trade represents a 3.32% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders have sold 53,923 shares of company stock worth $18,072,087. Insiders own 1.20% of the company’s stock.

Alnylam Pharmaceuticals Stock Down 0.4%

Alnylam Pharmaceuticals stock opened at $322.38 on Wednesday. The company has a debt-to-equity ratio of 1.28, a current ratio of 2.76 and a quick ratio of 2.71. Alnylam Pharmaceuticals, Inc. has a fifty-two week low of $205.87 and a fifty-two week high of $495.55. The firm has a fifty day moving average price of $349.24 and a two-hundred day moving average price of $412.24. The firm has a market cap of $42.75 billion, a price-to-earnings ratio of 188.53 and a beta of 0.36.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its quarterly earnings results on Thursday, February 12th. The biopharmaceutical company reported $1.25 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.43 by ($0.18). Alnylam Pharmaceuticals had a net margin of 6.43% and a return on equity of 69.02%. The business had revenue of $1.10 billion during the quarter, compared to analyst estimates of $1.16 billion. During the same period in the prior year, the business posted ($0.65) earnings per share. The company’s revenue for the quarter was up 84.9% compared to the same quarter last year. As a group, analysts forecast that Alnylam Pharmaceuticals, Inc. will post -1.7 earnings per share for the current year.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.